Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With.

Slides:

Advertisements

Similar presentations

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Advertisements

Volume 79, Issue 1, Pages (January 2013)

Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma Kazuya Takamochi, MD, Shiaki Oh, MD,

High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules Chunyan Wu, MD, Chao Zhao, MD, Yang Yang,

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R

Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC Kai Chen, MD, Fei Zhou, MD, Wenxiang Shen,

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

Outcomes of per-oral endoscopic myotomy for treatment of esophageal achalasia with a median follow-up of 49 months Quan-Lin Li, MD, Qiu-Ning Wu, MD,

Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations

SC17.02 Lung Cancer in China: Challenges and Perspectives

EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients Natalia Sutiman, BSc, Shao.

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer Mian Xie, MD, PhD, Li Zhang, MD, Chao-Sheng He, MD, Jin-Hui Hou, MD,

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR- Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC Si-Yang Liu, MD, Lan-Ying Gou, MD, An-Na Li, MD, Na-Na Lou, MMed, Hong-Fei.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Pooled Analysis of the Prognostic and Predictive Value of KRAS Mutation Status and Mutation Subtype in Patients with Non–Small Cell Lung Cancer Treated.

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

P3.02b-016 An Exploration Study of Mechanisms Underlying Primary Resistance to EGFR-TKIs in Patients Harboring TKI-Sensitive EGFR Mutations Ee Ke, Zhihong.

Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies Zhong-Yi Dong, PhD, Chao Zhang, MD,

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

P Typical Morphological Features Revealed Unfavorable Survival Benefits in High-Grade Neuroendocrine Carcinomas Hao-Ran Zhai, Jia-Tao Zhang,

Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based.

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Survival Benefit of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer: An Updated Meta-Analysis of 13 Randomized Control Trials Wei-An Song, MD,

Effusion Immunocytochemistry as an Alternative Approach for the Selection of First-Line Targeted Therapy in Advanced Lung Adenocarcinoma Tzu-Hsiu Tsai,

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary.

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations Chao-Hua.

EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases Tao.

Journal of Thoracic Oncology

Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External.

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial Kenneth S. Thress, PhD, Vivien.

Prophylactic Cranial Irradiation for Patients with Surgically Resected Small Cell Lung Cancer Jianlin Xu, MD, Haitang Yang, MD, Xiaolong Fu, MD, Bo Jin,

MA17.05 Evolutionary Trajectories of Molecular Progression in Different Subtypes of Primary Lung Adenocarcinomas Hao-Ran Zhai, Shiyong Li, Bing Liao,

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

A Multicenter, Open-Label, Randomized Phase II Controlled Study of rh-Endostatin (Endostar) in Combination with Chemotherapy in Previously Untreated Extensive-Stage.

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung.

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis Bin-Chi Liao,

Final Overall Survival Results from a Phase III, Randomized, Placebo-Controlled, Parallel-Group Study of Gefitinib Versus Placebo as Maintenance Therapy.

A Comprehensive Investigation of Molecular Features and Prognosis of Lung Adenocarcinoma with Micropapillary Component Yang Zhang, MD, Rui Wang, PhD,

Tumor Spread through Air Spaces Affects the Recurrence and Overall Survival in Patients with Lung Adenocarcinoma >2 to 3 cm Chenyang Dai, MD, Huikang.

Natural History and Factors Associated with Overall Survival in Stage IV ALK- Rearranged Non–Small Cell Lung Cancer Jose M. Pacheco, MD, Dexiang Gao,

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta- analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in.

MET Expression Plays Differing Roles in Non–Small-Cell Lung Cancer Patients with or without EGFR Mutation Ling Huang, MS, She-Juan An, PhD, Zhi-Hong.

EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer Yan.

Monotherapy Administration of Sorafenib in Patients With Non–Small Cell Lung Cancer (MISSION) Trial Luis Paz-Ares, MD, Vera Hirsh, MD, Li Zhang, MD,

Chemotherapy Response in East Asian Non-small Cell Lung Cancer Patients Harboring Wild-Type or Activating Mutation of Epidermal Growth Factor Receptors

Driven by Mutations: The Predictive Value of Mutation Subtype in EGFR-Mutated Non– Small Cell Lung Cancer Emily Castellanos, MD, Emily Feld, MD, Leora.

KRAS Mutations in Advanced Nonsquamous Non–Small-Cell Lung Cancer Patients Treated with First-Line Platinum-Based Chemotherapy Have No Predictive Value

Highly Sensitive Detection of EGFR T790M Mutation in Pre-TKI Specimens of EGFR- Mutated NSCLC: In Cis, In Trans, or a Different Clone? Alvaro Leone, BSc.D

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping Wei Jin, MD, Benjie Shan, MD, Hu Liu, PhD, Shoubing Zhou, PhD, Wenjuan.

P Combined Molecular and Radiological Evaluation Unveils Three Subtypes of Disease Progression to a Third Generation EGFR TKI Y. Zhang, Q. Zhou,

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Presentation transcript:

Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation Shan Su, PhD, Zhong-Yi Dong, PhD, Zhi Xie, MMed, Li-Xu Yan, PhD, Yu-Fa Li, MD, Jian Su, MMed, Si-Yang Liu, PhD, Kai Yin, MD, Rui-Lian Chen, MD, Shu-Mei Huang, MD, Zhi-Hong Chen, MMed, Jin-Ji Yang, PhD, Hai-Yan Tu, MD, Qing Zhou, PhD, Wen-Zhao Zhong, PhD, Xu-Chao Zhang, PhD, Yi-Long Wu, MD Journal of Thoracic Oncology Volume 13, Issue 11, Pages 1668-1675 (November 2018) DOI: 10.1016/j.jtho.2018.07.016 Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Flow chart of the study. PD-L1, programmed death ligand 1; GLCI, Guangdong Lung Cancer Institute; TKI, tyrosine kinase inhibitor. Journal of Thoracic Oncology 2018 13, 1668-1675DOI: (10.1016/j.jtho.2018.07.016) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Kaplan–Meier survival analysis of associations between programmed death ligand 1 (PD-L1) expression and progression-free survival (PFS) among patients with NSCLC. (A), Overall patient population. (B) Patients with exon 19 deletion. (C) Patients with the L858R mutation. Patients were divided into three groups by PD-L1 expression: TC3/IC3, TC1-2/IC1-2, and TC0/IC0. HR, hazard ratio; CI, confidence interval. Journal of Thoracic Oncology 2018 13, 1668-1675DOI: (10.1016/j.jtho.2018.07.016) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 The relationship between programmed death ligand 1 expression and progression-free survival (PFS) among patients who received EGFR–tyrosine kinase inhibitors for EGFR-mutant NSCLC. Journal of Thoracic Oncology 2018 13, 1668-1675DOI: (10.1016/j.jtho.2018.07.016) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Presentation of a case with EGFR L858R mutation. TKI, tyrosine kinase inhibitor; PR, partial response; PD-L1, programmed death ligand 1; c-MET, mesenchymal epithelial transition; T790M, substitution of methionine for threonine at position 790; CD8, cluster of differentiation 8. Journal of Thoracic Oncology 2018 13, 1668-1675DOI: (10.1016/j.jtho.2018.07.016) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Data 3 Journal of Thoracic Oncology 2018 13, 1668-1675DOI: (10.1016/j.jtho.2018.07.016) Copyright © 2018 International Association for the Study of Lung Cancer Terms and Conditions